



Marc A. Dall'Era, M.D.

Clinical Interests Dr. Dall'Era specializes in the management of malignant disease of the urinary tract. The specialty care Dr. Dall'Era offers includes:

- Multi-disciplinary and comprehensive care of patients with urologic malignancy
- Active surveillance for low risk prostate cancer
- Multi-parametric MRI/US fusion targeted prostate biopsy
- Blue Light Fluorescent cystoscopy for bladder cancer with Cysview
- Minimally invasive and robotic surgery of the kidney and prostate including prostatectomy, partial nephrectomy, pyeloplasty/ureteral reconstruction
- Radical cystectomy and neobladder creation
- Advanced genomics testing of urologic cancers

Research/Academic Interests Dr. Dall'Era's research interests include active surveillance for prostate cancer including utilization of mp-MRI and biomarker discovery and validation. He is also involved in translational research for urothelial cancer diagnosis and management including advanced genomics analysis of bladder tumors.

Title Vice Chair, Department of Urologic Surgery
Professor

Specialty [Cancer](#), Urologic Oncology, [Urology](#), Robotic Surgery, Surgery - Robotic

Department [Urologic Surgery](#)

Division Urology

Center/Program Affiliation [UC Davis Comprehensive Cancer Center](#)

Address/Phone Lawrence J. Ellison Ambulatory Care Center, 4860 Y St. Suite 2200 Sacramento, CA 95817
Phone: 916-734-2222

UC Davis Comprehensive Cancer Center, 2279 45th Street Sacramento, CA 95817
Phone: 916-734-5959

Additional Phone Physician Referrals: 800-4-UCDAVIS (800-482-3284)



Marc A. Dall'Era, M.D.

Education	M.D., UC Davis, Davis CA 2000 B.S., UC Davis, Davis CA 1995
Internships	General Surgery, University of Washington, Seattle WA 2000-2001
Residency	Urology, University of Washington, Seattle WA 2001-2005
Fellowships	Oncology, UC San Francisco, San Francisco CA 2006-2008
Board Certifications	American Board of Urology
Professional Memberships	American Association of Clinical Urologists American Urological Association Data and Safety Monitoring Board for the Prostate, Board Member Genitourinary (GU) Cancers Symposium News Planning Society of Urologic Oncology (SUO), Committee Member - Prostate Cancer Committee Society of Urologic Oncology (SUO), Spring Scientific Program Co-Chair Western Section American Urological Association, Board of Directors
Select Recent Publications	To view a detailed list of Dr. Dall'Era's publications, please click here .

Dall'Era, MA, Klotz, L. Active surveillance for intermediate-risk prostate cancer. *Prostate Cancer and Prostatic Diseases*. 2017;20(1):1-6.

Yap, SA, Yuh, LM, Evans, CP, Dall'Era, MA, Wagenaar, RM, Cress, R, Lara, PN. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. *World Journal of Urology*. 2017;35(2):277-283.

Pugashetti, N, Chandrasekar, T, Lurvey, R, Durbin-Johnson, B, Dall'Era, M, de Vere White, R, Evans, C, Yap, S. Perioperative Outcomes Following Neoadjuvant Chemotherapy and Radical Cystectomy-Is There Room for Improvement? *Urology Practice Journal*. 2016;3:364-370.

Pan, A, Zhang, H, Li, Y, Lin, T, Wang, F, Lee, J, Cheng, M, Dall'Era, M, Li, T, de Vere White, R,



Marc A. Dall'Era, M.D.

Pan, C, Lam, K. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. *Nanotechnology*. 2016;27(42): 1-9.

Chandrasekar, T, Pugashetti, N, Durbin-Johnson, B, Dall'Era, MA, Evans, CP, de Vere White, RW, Yap, SA. Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? *Bladder cancer (Amsterdam, Netherlands)*. 2016;2(4): 441-448.

Chow, H, Ghosh, PM, de Vere White, R, Evans, CP, Dall'Era, MA, Yap, SA, Li, Y, Beckett, LA, Lara, PN, Pan, CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. *Cancer*. 2016;122(12):1897-904.

Marc A. Dall'Era, Benjamin J. Davies. Clinical Case Discussion: Intermediate-Risk Prostate Cancer: The Case for Active Surveillance. *European Urology Focus*. 2015;1(2):208-209.

Dall'Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A retrospective Chart Review Analysis. *Urology Practice*. 2015;2: 343-348.

Yuh L, Dall'Era MA, Penson DF, Evan CP. Active Surveillance for Prostate Cancer Under the Patient Protection and Affordable Act. *Urology Practice*. 2015;2(4):154-159.

Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall'Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. *Canadian Urological Association Journal*. 2015;9(3-4):E204-207.

© 2021 UC Regents